A panel discussion on “Communicating with Payers: Practical Guidance for Sparsentan Access in FSGS” provided guidance on aligning payer coverage with the evidence behind sparsentan.
Dr. Campbell asked how payer coverage criteria should be worded given the gap between DUPLEX‘s trial inclusion rules and the broader FDA label.
Dr. Trachtman argued that if a patient has proteinuria above 1.5 grams and a physician prescribes sparsentan, coverage should follow, with clinical judgment guiding use rather than the trial’s stricter enrollment criteria.
Dr. Trachtman stressed that careful, timely follow-up should justify continued coverage rather than closing the door on the drug outright, placing the burden on practitioners to confirm effectiveness and safety over time.
Asked for practical advice on communicating with payers, Dr. Trachtman pointed clinicians toward the DUPLEX summary data as the strongest available evidence, and urged providers to advocate directly for patients.
He noted that confirmed FSGS carries roughly a 40% to 50% chance of progressing to kidney failure within five to ten years and sparsentan remains the only approved therapy.
Dr. Trachtman called for collaboration with patient advocacy groups to help payers recognize that risk, alongside disciplined monitoring so resources aren’t wasted on ineffective treatment.
Related: Scientists Identify New Pathway to Combat Liver Inflammation
He emphasized that real-world, post-approval data on proteinuria reduction and kidney function preservation will be essential for updating both the FDA and payers as more evidence accumulates over time.
Untreated, unresponsive FSGS carries real costs.
As Dr. Trachtman noted, these costs can outweigh a drug’s sticker price, including lost work and school time and progression to end-stage disease.
Dr. Campbell agreed, noting a promising therapeutic pipeline behind sparsentan and expressing hope that FSGS care is entering a precision-medicine era with multiple treatment options ahead for patients.
Dr. Trachtman called DUPLEX‘s completion a monumental accomplishment and the first step in an ongoing dialogue between patients, regulators, and payers, rather than a finished answer.
The completion of the DUPLEX trial and the approval of sparsentan represent significant milestones in the treatment of FSGS, and the panel’s discussion provides a valuable framework for considering the implications of these developments for clinical practice and patient care.
Thank you for watching this Managed Healthcare Executive Between The Lines series on focal segmental glomerulosclerosis. Please subscribe to our eNewsletter for information on upcoming video series.
